"10.1371_journal.pone.0058932","plos one","2013-03-15T00:00:00Z","Wan C Tan; Jean Bourbeau; Paul Hernandez; Kenneth R Chapman; Robert Cowie; J Mark FitzGerald; Shawn Aaron; Darcy D Marciniuk; Francois Maltais; A Sonia Buist; Denis E O’Donnell; Don D Sin","UBC James Hogg Research Laboratories, Providence Heart+Lung Institute, St. Pauls Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montréal, Quebec, Canada; Respiratory Division, Department of Medicine, QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada; Asthma & Airway Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada; Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; University of British Columbia, Institute for Heart and Lung Health, Vancouver, British Columbia, Canada; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada; Division of Respirology, Critical Care and Sleep Medicine, and Airway research Group, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Centre de Pneumologie, Institute Universitaire de Cardiologie et de Paneumologie de Quebec, Quebec City, Quebec, Canada; Oregon Health and Science University, Portland, Oregon, United States of America; Division of Respiratory & Critical Care Medicine, Queens University, Kingston, Ontario, Canada","¶ Membership of the CanCOLD Collaborative Research Group is provided in the Acknowledgments.","The authors have read the journals policy and have the following conflicts: Wan C. Tan has received funding for the Canadian Obstructive Lung Disease epidemiological study Operations from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca. Dr. Kenneth Chapman holds the GSK-CIHR Research Chair in Respiratory Health Care Delivery at the University Health Network, Toronto, Canada. In the past five years, Dr. Marciniuk received funding support to attend a symposium from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, and Pfizer; for speaking from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, and Pfizer; for consulting from AstraZeneca, Canadian Agency for Drugs and Technology in Health, GlaxoSmithKline, Health Canada, Health Quality Council, Novartis, Nycomed, Pfizer, Public Health Agency of Canada, Saskatchewan Medical Association and the Saskatoon Health Region; for research (directed to the University of Saskatchewan) from AstraZeneca, Boehringer Ingelheim, Canadian Agency for Drugs and Technology in Health, Canadian Institute of Health Research, Dalhousie University, Forest Research, GlaxoSmithKline, Lung Association of Saskatchewan, McGill University, Nycomed, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering, Pfizer, and the University of Alberta; and for organizing education from the American College of Chest Physicians, Boehringer Ingelheim, Canadian Thoracic Society, Merck, Nycomed, and the University of Saskatchewan. Dr. Marciniuk is an employee of the University of Saskatchewan. A.S. Buist has received unrestricted educational grants from GlaxoSmithKline (GSK), AstraZeneca (AZ), Novartis, Chiesi, Merck, Boehringer Ingelheim to the BOLD operation Center at Kaiser Center for health Research, Portland, Oregon, and served on advisory boards for GSK, Merck, Novartis and AZ. Denis ODonnell has served on advisory boards for Boehringer Ingelheim, Pfizer, GSK, Novartis, and Nycomed; has received lecture fees from Boehringer Ingelheim, Astra Zeneca, Pfizer, and GSK; and has received industry-sponsored grants from Boehringer Ingelheim, GSK, and Merck Frosst Canada and from Novartis and Pfizer. Paul Hernandez has participated during the past five years on medical advisory boards for Actelion, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, and Pfizer; has conducted clinical research funded by &SetFont Typeface=43;Actelion, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, GlaxoSmithKline, Novartis, Nycomed, and Pfizer; and received support to travel to ERS Congress from AstraZeneca. Jean Bourbeau, Francois Maltais, Don D. Sin, Robert Cowie, J. Mark FitzGerald, Shawn Aaron have no conflict of interest to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Wan C Tan","WCT",12,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
